Featured Research

from universities, journals, and other organizations

Working towards personalized cancer treatment

November 12, 2013
University of Oslo
Extensive statistical analyses of the mutation distribution in several thousand cancerous tumors make it possible to find cures for types of cancer that cannot be treated today.

Cancerous tumors are different. Large variations in mutation can be found among individual cancerous cells. In addition, cancer cells' reaction to treatment varies: sometimes the treatment works, while at other times it only makes things worse.

Related Articles

"We all have a unique composition of hereditary variants of genes that affects how both our body and the tumor react to cancer treatment," Ola Myklebost tells us. He is Professor of Molecular Biology in the Department of Biosciences at the University of Oslo, and also holds a post at the Institute for Cancer Research at Oslo University Hospital. Professor Myklebost has now received a grant of NOK 75 million from the Research Council of Norway to develop the idea for next generation cancer treatment -- personalized cancer therapy, directed specifically towards the various mutation faults in cancerous tumors. This is a national research project for personalized cancer medicine called the Norwegian cancer genomics consortium

"Today's treatment most often utilizes broad-spectrum chemotherapy against all tumors. Targeted treatment that is specially selected for the individual tumor can be effective against a very specific mechanism."

Myklebost is now in particular investigating the mutations in tumors from patients with extremely rare types of cancer.

"Our dream is to provide more precise treatment. When only a few patients suffer from a disease there is often little commercial interest in developing medicines. We want to expand the use of targeted treatment against several types of cancer. This means that more patients can be treated for high-risk types of cancer for which the current treatment option is inadequate. For example we hope that intestinal cancer medicine can also be used against other forms of cancer, but due to complex regulatory mechanisms in various types of cells we're not sure it will work.," Myklebost says to the research magazine Apollon.

Helping those with soft tissue sarcomas

Examples of types of cancer with poor odds are lung cancer, pancreatic cancer and sarcomas. Sarcomas are soft tissue cancer, a type of cancer that affects at least 200 Norwegians a year -- children more often than adults.

"We hope to find the same mutations in patients with sarcomas as we do in those with other types of cancer for which treatment is available today. Sarcoma patients can then perhaps be given the same treatment."

To find this out, Myklebost's research group will use DNA sequencing on tumors from as many sarcoma patients as possible. They will examine patients from the whole of Norway. So far they have collected DNA samples from both cancerous and healthy tissue from several hundred patients.

"We have to know which gene variants are normal in order to find the mutations that are only relevant for tumors."

Provided that the sequencing machine is in function 24 hours a day, the work of DNA sequencing a thousand samples will take a year.

The researchers will define a thousand genes that may be related to cancer diseases. They will make no progress if they only compare the DNA of healthy and cancerous tissue from one patient: they must analyze the DNA connection between all the patients to find out which mutations can lead to cancer.

Only a fraction of the genome is genes. In the approximately 20,000 genes we all have there is everything from a few to several tens of thousands of mutations in the cancer cells. The question is which mutations are to be treated. During their work the researchers have found large mutation differences among the cells in the same tumor.

"We can point to mutations that are only found in a quarter of the cells. If you select treatment that only hits three-quarters of the cells, the remaining quarter will be able to grow and become resistant. Then the patient will have a relapse," Professor Myklebost tells us, and continues, "If we find mutations for a certain form of treatment, we contact the doctors in charge to give them the information, but we have no funds for structured clinical trials."

All Norwegian cancer patients

In the next phase, Myklebost wants the health service to analyze the DNA of the tumors of all the 26,000 Norwegians who are diagnosed with cancer each year.

"This will give us opportunities that are unique on a global basis."

The collection of the DNA samples requires comprehensive logistics at the hospitals. Pathologists send in tumor samples either frozen or paraffin-embedded.

"The best thing would be samples from surgical interventions. The problem is that if the patients has already been treated with chemotherapy then the cells are often dead. And we'll do far more than the pathologists: while they only examine a few genes today, we want to analyze at least a thousand."

Ola Myklebost is now part of a national consortium and is working on spreading the sequencing technology to all the health regions.

Enormous calculations

Gene interpretation demands enormous statistical analyzes on computers that have a huge capacity for calculation. The limitation today is precisely the lack of access to such high-performance computing, as well as the storage of large amounts of data.

Bearing in mind that our genome has 20,000 genes and that a cancerous tumor is due to not only one mutation but to the combination of many, the researchers must gather enormous amounts of data to enable them to produce statistical information that is sufficiently accurate. Such analyzes demand massive calculations.

Gene therapy is expensive

Precision treatment is of course more expensive than traditional cancer treatment.

"The advantage is less wasted treatment. If we avoid half of the current wrong treatment, it won't be dearer in total even though precision treatment is twice as expensive. So it's not certain that our method will lead to more expensive treatment. And even if our analyzes were to cost some tens of thousands of Norwegian kroner, it isn't more than MRI scans. And it's far cheaper that unsuccessful treatment," is Professor Myklebost's opinion.

Story Source:

The above story is based on materials provided by University of Oslo. Note: Materials may be edited for content and length.

Cite This Page:

University of Oslo. "Working towards personalized cancer treatment." ScienceDaily. ScienceDaily, 12 November 2013. <www.sciencedaily.com/releases/2013/11/131112090813.htm>.
University of Oslo. (2013, November 12). Working towards personalized cancer treatment. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2013/11/131112090813.htm
University of Oslo. "Working towards personalized cancer treatment." ScienceDaily. www.sciencedaily.com/releases/2013/11/131112090813.htm (accessed March 31, 2015).

Share This

More From ScienceDaily

More Health & Medicine News

Tuesday, March 31, 2015

Featured Research

from universities, journals, and other organizations

Featured Videos

from AP, Reuters, AFP, and other news services

Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.


Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News


Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile

Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins